PharmaJet, AMRIID cooperating on needle-free smallpox vaccine

PharmaJet, Inc., and the U.S. Army Medical Research Institute of Infectious Diseases have signed a cooperative research and development agreement to combine PharmaJet’s needle-free jet injection delivery system and USAMRIID’s candidate gene-based smallpox vaccine.

The USAMRIID vaccine, patented under the name 4pox, is a combination of genes that, when delivered together, can provide protection from orthopoxviruses like the monkeypox and vaccinia viruses when used in animal models.

Led by USAMRIID’s Dr. Jay Hooper, four different co-delivered immunogens will be tested for immune responses using a PharmaJet needle-free intradermal delivery system.

The test will compare new data with existing data that has been produced by PharmaJet and alternative devices.

“PharmaJet is very pleased to continue to work with USAMRIID,” Linda McAllister, the acting CEO of PharmaJet, said. “We are very excited about the potential for our needle-free, jet injection, intradermal technology to contribute to the efficacy of this important new class of DNA-based vaccines.

The field of gene-based molecular vaccines continues to search for effective, practical and safe delivery technologies, and the 4pox gene-based vaccine has already been evaluated in preclinical models using muscle and skin electroporation and gene gun technology. PharmaJet’s needle-free technology may also be evaluated for other DNA vaccines of military importance, which could be added in addendums to the current CRADA.